Clinical Trial

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-05-08; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Recruiting 2025-07-03
Trial Details
NCT Number NCT06964009
Lead Sponsor Elizabeth Stover, MD, PhD
Collaborators: United States Department of Defense, Dialectic Therapeutics, Inc, American Society of Clinical Oncology
Conditions Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
Enrollment 30 participants
Start Date 2025-09-22
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-21